For certain types/stages of cancer, knowing PD-L1 expression may help identify patients that will benefit most from immune checkpoint blockade.1-8
LEARN MORE about the PD-L1 pathway and PD-L1 blockade
*Characterization of low expression may vary by diagnostic assay.
Testing for PD-L1
1. Massard C, Gordon MS, Sharma S, et al. Safety and efficacy of durvalumab (MEDI4736), an anti–programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer. J Clin Oncol. 2016;34(26):3119-3125. 2. Petrylak DP, Powles T, Bellmunt J, et al. A phase 1a study of atezolizumab (MPDL3280A/anti-PDL1): updated response and survival data in urothelial bladder cancer. Presented at: American Society of Clinical Oncology (ASCO) Annual Meeting; May 29-June 2, 2015. Chicago, IL. http://meetinglibrary.asco.org/content/148074-156. Accessed October 16, 2016. 3. Rosenberg JE, Hoffman-Cnesits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016;387(10031):1909-1920. 4. Plimack ER, Bellmunt J, Gupta S, et al. Pembrolizumab (MK-3475) for advanced urothelial cancer: updated results and biomarker from KEYNOTE-012. Presented at: American Society of Clinical Oncology (ASCO) Annual Meeting; May 29-June 2, 2015. Chicago, IL. http://meetinglibrary.asco.org/content/111950. Accessed October 16, 2016. 5. Powles T, Eder JP, Fine GD, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 2014;515(7528):558-562. 6. Rosenberg J, Bono P, Kim J, et al. Nivolumab monotherapy in metastatic urothelial carcinoma: updated efficacy by subgroups and safety results from the CheckMate 032 study. Poster presented at: European Society for Medical Oncology (ESMO) Congress; October 7-11, 2016; Copenhagen, Denmark. 7. Sharma P, Callahan MK, Bono P, et al. Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. Lancet Oncol. 2016;17(11):1590-1598. 8. Kim H, Kwon HJ, Park SY, Park E, Chung JH. PD-L1 immunohistochemical assays for assessment of therapeutic strategies involving immune checkpoint inhibitors in non-small cell lung cancer: a comparative study. Oncotarget. 2017;8(58):98524. 9. Levy BP, Chioda MD, Herndon D, et al. Molecular testing for treatment of metastatic non-small cell lung cancer: how to implement evidence-based recommendations. Oncologist. 2015;20(10):1175-1181. 10. American Cancer Society. What is bladder cancer? https://www.cancer.org/cancer/bladder-cancer/about/what-is-bladder-cancer.html. Accessed June 21, 2017. 11. Montironi R, Santoni M, Tartari F, et al. Testing PD-1/PD-L1 expression in cancer therapy: pathologic insights and economic sustainability. Arch Pathol Lab Med. 2106;140(6):501-502.